Pembrolizumab (Keytruda), an anti–PD-1 therapy, may be effective as monotherapy in patients with advanced unresectable nasopharyngeal carcinoma whose tumors express programmed cell death-ligand 1 (PD-L1). Data from a phase Ib study, KEYNOTE-028, showed an overall response rate of 22.2% in 27...
Patients with cancers of the mid and lower throat may have higher survival rates if their initial treatment includes surgery, according to new research (Abstract 2804) presented at the 2015 European Cancer Congress in Vienna, Austria. Researchers explained that a nationwide study in Taiwan found...
A new marker already linked to other types of cancer was found to play a role in the most common childhood primary tumor inside the eye, researchers at the University of Michigan Health System have found. Their findings were published by Khan et al in Laboratory Investigation. Retinoblastoma is a...
In a prospective cohort study reported in JAMA Oncology, Rettig et al found that persistent human papillomavirus (HPV) type 16 DNA in post-treatment oral rinses was associated with a poorer prognosis in patients with HPV-related oropharyngeal cancer. The study included 124 patients treated with...
As reported in The New England Journal of Medicine, Gara et al identified a germline HABP2 mutation as a susceptibility gene for familial nonmedullary thyroid cancer. Identification of HABP2 Variant In a kindred study, whole-exome sequencing was performed using peripheral blood DNA from affected...
In their bid to find the best combination of therapies to treat anaplastic thyroid cancer, researchers at Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal. In testing multiple HDAC inhibitors in combination with the chemotherapy drug...
A study of long-term thyroid cancer outcomes shows, among other findings, that moderate suppression of thyroid-stimulating hormone, which drives the disease, may be as beneficial as more extreme hormone suppression. Extreme thyroid-stimulating hormone suppression is associated with increased side...
Despite findings of previous studies and published guidelines, nearly two-thirds of patients with T4a laryngeal cancer are not receiving a total laryngectomy—the recommended form of treatment—and, as a result, have significantly worse survival rates vs those treated with a total...
On the hunt for better cancer screening tests, Johns Hopkins scientists led a proof-of-principle study that successfully identified tumor DNA shed in the blood and saliva of 93 patients with head and neck cancer. A report on the findings was published by Wang et al in Science Translational...
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital (MGH) Cancer Center may have...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers, as research now shows TLR4 can either promote or inhibit breast cancer cell growth depending on mutations in...
Patients older than age 45 with thyroid cancer that has spread to neck lymph nodes have long been considered at higher risk of dying, but the same has not been true for younger patients. Now researchers at the Duke Cancer Institute and the Duke Clinical Research Institute have found that...
A study by Dahlstrom et al investigating the usefulness of serum antibodies to human papillomavirus (HPV)-16 DNA antigens as predictors of survival for patients with oropharyngeal carcinoma has found that E1, NE2, and E6 antibody positivity were all strongly associated with improved overall and...
A randomized phase III study resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer by showing that elective neck dissection both improves survival and lowers recurrence rates compared to therapeutic neck dissection performed...
Immunotherapy with pembrolizumab (Keytruda) produced a clinically meaningful overall response rate in a study among 132 patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The overall objective response rate was 24.8%, and 57% of patients experienced some tumor...
In an updated patient-level meta-analysis reported in The Lancet Oncology, Blanchard et al of the Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC) collaborative group found that the addition of chemotherapy to radiotherapy improved overall survival in patients with nasopharyngeal ...
The new nine-valent human papillomavirus (HPV) vaccine (Gardasil 9) can potentially prevent 80% of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. Additionally, the new vaccine, which includes seven cancer-causing...
In the phase III LUX-Head & Neck 1 trial reported in The Lancet Oncology, Machiels et al found that afatinib (Gilotrif) improved progression-free survival vs methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum...
Vaccination of women aged 18 to 25 with the human papillomavirus (HPV) vaccine resulted in strong protection against future infection at three anatomic sites among women without prior HPV exposure and may still offer some protection in those with evidence of prior exposure. These findings were...
A large, diverse study of 16,827 adolescents and young adults with differentiated thyroid cancer has found that African Americans and Hispanics were six times and three times more likely, respectively, to die of their cancer than Caucasians. Residing in low-socioeconomic neighborhoods, insurance...
Public health programs that devote a portion of their funding to encourage more boys to be vaccinated against human papillomavirus (HPV)—rather than merely attempting to raise coverage among girls—may ultimately protect more people for the same price, a study from Duke University...
In patients with previously irradiated recurrent squamous cell carcinoma of the head and neck, the combination of stereotactic body radiation therapy plus cetuximab (Erbitux) appears to be safe and effective, according to a study by Vargo et al in the International Journal of Radiation Oncology...
Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study published...
Current smoking and heavy alcohol consumption appear to be risk factors for prolonged use of a gastrostomy tube in patients with head and neck cancer undergoing radiotherapy or chemoradiotherapy. The findings were published in a report by O’Shea et al in JAMA Otolaryngology-Head & Neck...
A prospective, multicenter, observational study involving 992 consecutive patients with one to four asymptomatic, sonographically or cytologically benign thyroid nodules found that “the majority of nodules exhibited no significant size change during 5 years of follow-up or they actually...
Breast cancer survivors are at increased risk of developing thyroid cancer, especially within 5 years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results were presented at the Endocrine Society's 97th Annual Meeting. “Recognition of...
In a study reported in the Journal of Clinical Oncology, Huang et al showed that recursive portioning analysis (RPA) could be used to provide TNM stage grouping with improved prediction of survival in patients with human papillomavirus (HPV)-related nonmetastatic oropharyngeal carcinoma. ...
The U.S. Food and Drug Administration (FDA) today granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...
In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...
In the phase II CONCERT-2 trial reported in The Lancet Oncology, Giralt et al found that treatment with the EGFR inhibitor panitumumab (Vectibix) plus concurrent radiotherapy was associated with poorer local-regional control vs cisplatin chemoradiation in previously untreated patients with...
In the phase II CONCERT-1 trial reported in The Lancet Oncology, Mesía et al found that adding the EGFR inhibitor panitumumab (Vectibix) to standard cisplatin chemoradiation provided no benefit in previously untreated patients with unresected stage III to IVB head and neck squamous cell...
In patients with iodine-refractory papillary thyroid cancer, the addition of dabrafenib (Tafinlar) therapy was shown to stimulate radioiodine uptake in thyroid cancer cells, according to a report by Rothenberg et al in Clinical Cancer Research. This approach has the potential advantage of requiring ...
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...
Data from 25 case-control studies and separate analyses show that head and neck cancers in young adults are more likely to occur as a result of inherited factors rather than lifestyle factors, such as smoking or drinking alcohol, according to a new study by Toporcov et al published in the...
Oral infection with human papillomavirus 16 (HPV16), which is the type of HPV most frequently linked to HPV-driven head and neck cancers, was more likely to persist 12 or more months in men older than 45 than in those younger than 45, according to a study reported by Pierce Campbell et al in...
In a population-based study of patients with thyroid cancer, 12.3% of patients with small papillary thyroid tumors experienced thyroid cancer–related deaths despite undergoing thyroidectomy, according to a report by Nilubol and Kebebew in the journal Cancer. From the results of this study,...
In a study reported in the Journal of Clinical Oncology, Wuthrick et al found that patients with stage III or IV head and neck cancer in the Radiation Therapy Oncology Group (RTOG) 0129 trial who were treated at historically high-accruing centers in RTOG clinical trials had significantly better...
As reported in the Journal of Clinical Oncology by Nguyen-Tan et al, long-term follow-up in the phase III Radiation Therapy Oncology Group (RTOG) 0129 trial indicates no difference in overall survival or late toxicity with use of accelerated vs standard radiation therapy plus cisplatin in patients...
In a large retrospective study reported in the Journal of Clinical Oncology, Xing et al found that presence of the BRAF V600E mutation was an independent predictor of recurrence of papillary thyroid cancer. The study involved 2,099 patients with papillary thyroid cancer consecutively selected over ...
In a Surveillance, Epidemiology, and End Results (SEER) database analysis reported in JAMA Otolaryngology-Head & Neck Surgery, Sperry et al found that sentinel lymph node biopsy was not associated with improved disease-specific survival in propensity score–matched patients with head and...
A study investigating the prevalence and risk factors of oral human papillomavirus (HPV) infection among young men has found a higher prevalence of oral HPV among men who had female partners with an oral and/or genital HPV infection, suggesting that transmission may occur through oral or genital...
Scientists investigating the molecular mechanism of the protein p16 in cisplatin-treated head and neck cancer cells have found that the drug is able to kill the malignant cells by interacting with the protein gigaxonin. Although p16 is commonly produced in human papillomavirus (HPV)-positive...
At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for lenvatinib mesylate as a treatment for progressive radioactive iodine–refractory differentiated thyroid cancer and granted the application Priority Review status. Lenvatinib is an oral multiple...
The risk of developing cancer in a salivary gland might be higher in people with BRCA1 or BRCA2 mutations, which are associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...
A study involving a patient with metastatic anaplastic thyroid cancer who achieved a near-complete response to everolimus (Afinitor) that lasted for 18 months, followed by progressive disease, has revealed a previously unknown mutation in the TSC2 gene and in the mTOR protein. The discovery...
Elevated esophageal mucosa cyclooxygenase-2 (COX-2) levels appear to be associated with the presence of Barrett’s esophagus as well as high waist-to-hip ratios and current tobacco smoking, according to the results of a study reported by Nguyen et al in Digestive Diseases & Sciences. These ...
The tyrosine kinase inhibitor afatinib (Gilotrif) was significantly superior to methotrexate as second-line therapy in patients with advanced squamous cell carcinoma of the head and neck who progressed after platinum-based chemotherapy, according to results of the LUX-Head & Neck 1 trial. The...
In a population-based study reported in JAMA Otolaryngology-Head & Neck Surgery, Bann et al found that the average annual percent increase in thyroid cancer incidence in Pennsylvania approaches twice that in the rest of the country. The incidence of thyroid cancer in the United States has more...
Navidea Biopharmaceuticals, Inc, recently announced that technetium 99m tilmanocept (Lymphoseek Injection) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation...